Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

ABSTRACT: While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: "Triple negative" and ErbB2-overexpressing, are discussed in this review.

SUBMITTER: Hoeferlin LA 

PROVIDER: S-EPMC4012677 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature